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ABSTRACT  
Background: Polycystic ovary syndrome (PCOS) is a common endocrine disorder associated 
with increased risk of cardiovascular disease. The purpose of this study was to investigate the ef-
fects of omega-3 fatty acids on serum paraoxonase 1 activity and lipids ratios in polycystic ovary 
syndrome. 
Methods: This double-blind randomized controlled clinical trial was conducted on 64 PCOS pa-
tients with 20-35 years old. Thirty two of the subjects had taken 4 g/day omega -3 fatty acids and 
32 patients were given placebo for 8 weeks. Fasting blood samples, anthropometric measure-
ments and dietary intakes were collected at the beginning and the end of the study. Serum total 
cholesterol, triglyceride, and HDL-C were measured using the enzymatic methods. LDL-C con-
centration was calculated by the Friedewald formula and arylesterase activity of serum PON1 was 
measured. Data were analyzed using SPSS software. 
Results: Omega-3 fatty acids significantly decreased TC/HDL-C and LDL-C/HDL-C ratios (P 
= 0.009 for both) and significantly increased serum PON1 activity (P = 0.048) compared with 
placebo. Changes in TG/HDL-C ratio were not statistically significant in omega-3 fatty acids 
group at the end of the study in comparison to placebo group. Reduction in TC/HDL-C, LDL-
C/HDL-C and TG/HDL-C ratios and increase in serum PON1 activity were also significant in 
omega-3 fatty acids group at the end of the study compared with baseline values (P <0.001, P < 
0.001, P = 0.004, and P = 0.001, respectively). 
Conclusion: Omega-3 fatty acids may decrease the risk for cardiovascular disease through the 
improvement in paraxonase-1 activity and reduction in some lipids ratio in PCOS women. 
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Introduction 
 
Polycystic ovary syndrome (PCOS) is 
one of the most frequent endocrine disord-
ers in reproductive age women with a 
worldwide prevalence rate of 5%–10% [1]. 
PCOS is the main cause of female infertility 
due to anovulation [2]. PCOS and its asso-
ciated symptoms have a negative effect on 
health-related quality of life and cause social 
and emotional stress in affected women [1].  
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Hyperinsulinemia has an important 
role in pathogenesis of this disorder [3]. Sev-
eral risk factors including obesity, insulin 
resistance, dyslipidemia and oxidative stress 
lead to early onset of cardiovascular disease 
and type 2 diabetes in these women.  The 
risk of myocardial infarction has been re-
ported to increase by 7.4-fold in PCOS pa-
tients than normal [4].  
Oxidative stress arises from an imbal-
ance between pro-oxidant  molecules pro-
duced from cellular metabolism or exogen-
ous sources and antioxidants [5]. Several en-
zymes, vitamins and other biomarkers con-
stitute antioxidant defense of the body. 
Disturbance in this system may lead to mo-
lecular and cellular damage [6]. Oxidative 
stress may be involved in the pathogenesis 
of PCOS and female infertility [5, 6] and can 
affect a variety of physiological functions 
including folliculogenesis, androgen produc-
tion and hyperinsulinemia in women with 
PCOS [5, 6].  
Paraoxonase-1  (PON1) is an antioxi-
dant enzyme exists in the circulation bound to 
high-density lipoproteins cholesterol (HDL-C) 
and prevents lipid peroxidation. These actions 
suggest a protective role of PON1 against 
atherosclerosis [7]. Serum PON1 activity was 
lower in women with PCOS compared with 
healthy women [4, 8, 9].  
Increased dietary polyunsaturated fatty 
acids intake may be associated with im-
proved metabolic and endocrine characte-
ristics in women with PCOS [10]. Eicosa-
pentaenoic acid (EPA) and docosahexaenoic 
acid (DHA) are long chain omega-3 polyun-
saturated fatty acids found in fatty fish [11]. 
Growing body of evidence indicate that an 
increased intake of  EPA and EDA could 
impact positively on the human health [12]. 
Omega-3 fatty acid supplementation 
had a beneficial effect on some cardiometa-
bolic risk factors in women with PCOS [13]. 
The positive effects of omega-3 fatty acids 
on antioxidant enzymes are repoted [14, 15]. 
Fish oil supplementation caused remarkable 
increase in serum PON1 levels in familial 
combined hyperlipidemia [16]. However, 
little is known about the effects of omega-3 
fatty acids on PON1 activity. 
Considering that oxidative stress in 
combination with impaired lipid profile are 
contributed in metabolic complication of 
PCOS, and the effects of omega-3 fatty ac-
ids on serum PON1 activity in PCOS pa-
tients have not yet been investigated, the 
objectives of this study were to determine 
the effects of omega-3 fatty acids on serum 
paraoxonase 1 activity and lipids ratios in 
polycystic ovary syndrome. 
 
Materials and Methods 
 
Study population 
Sixty-four PCOS patients were re-
cruited in this double-blind randomized 
controlled clinical trial from outpatient De-
partment of Obstetrics of Alzahra Hospital 
in Tabriz, Iran. The registration ID of this 
study in Iranian Registry of Clinical Trials 
was: IRCT201011083664N3.  
The inclusion criteria were 20-35 yr 
old PCOS patients, with body mass index 
(BMI) ranging from 25 to 40 kg/m
2. The 
diagnosis of PCOS was established accord-
ing to 2003 Rotterdam criteria, which re-
quire at least two of three features for diag-
nosis: chronic anovulation, clinical or bio-
chemical signs of hyperandrogenism, and 
polycystic ovaries in ultrasonography [17]. 
The study exclusion criteria included smok-
ing, pregnancy, using fish oil and other die-
tary supplements with the past 3 months 
and during the study, history of diseases in-
cluding diabetes, liver, kidney and cardiovas-
cular diseases, thyroid disorders, hyperpro-
lactinemia, cushing׳s syndrome and use of 
any medications. Subjects were asked to 
maintain their usual dietary intakes and 
physical activity throughout the study.  
Ethical Committee of Tabriz Univer-
sity of Medical Science approved the study 
protocol. Written informed consent ob-
tained from each subjects prior to study. 
 
Study design 
The participants were randomly allo-
cated in two groups using a block randomi-Health Promotion Perspectives, Vol. 2, No. 2, 2012; P: 197-204  
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zation procedure with matched subjects in 
each block based on BMI and age. A general 
questionnaire was completed for each sub-
ject. Body weight was measured using a scale 
(Seca, Germany), without shoes and wearing 
light clothing. Height was measured using a 
mounted tape without shoes. BMI was cal-
culated as the weight in kg divided by the 
height in meters squared. Information about 
daily energy and macronutrient intakes were 
obtained by 24-hour recall method for 3 
days, including 2 week day and 1 weekend. 
Amounts of all consumed foods were cal-
culated in gram and data were interred in 
Nutritionsit 4 software. Then energy and 
macronutrient content of all foods were de-
termined by software and three day averages 
of dietary intakes were calculated.  
The blood sampling (5 ml) was con-
ducted after 12 hours of fasting at 7 and 10 
a.m. The serum was separated by centrifu-
gation and stored at  −70  °C  until  further 
analysis. Subjects in omega-3 fatty acids 
group (n=32) were taken 4 g daily of omega-
3 fatty acids ( 4× 1000 mg capsules, each 
capsule contained 180 mg EPA and 120 mg 
DHA, Good Health Company, USA ) for 8 
weeks and placebo group (n=32) was given 
placebo capsules contained 500 mg paraffin 
oil for the same period. All anthropometric, 
dietary intakes and biochemical measure-
ments were assessed again at the end of in-
tervention period in both groups. 
 
Biochemical measurements 
Serum total cholesterol (TC), triglyce-
ride (TG), and HDL-C were measured using 
the standard enzymatic methods by Pars 
Azmun kits (Karaj, Iran). Low-density lipo-
protein cholesterol (LDL-C) concentration 
was determined by the Friedewald formula: 
LDL-C = TC – (HDL-C+TG/5) [19]. The 
TC/HDL-C, LDL-C/HDL-C and 
TG/HDL ratio were calculated for all sub-
jects. Arylesterase activity of serum PON1 
was measured by spectrophotometric me-
thod using phenyl acetate as the substrate 
and absorbance was monitored at 270 nm 
and 37 ℃. 
Three patients were excluded from the 
study because of personal reasons. Sixty one 
patients (n = 30 in omega-3 fatty acids 
group and n = 31 in placebo group) com-
pleted the study. 
 
Statistical analysis 
Data were analyzed using SPSS soft-
ware (version 11.5; SPSS Inc., Chicago, IL) 
and the results are expressed as mean ± 
standard deviation. The normality of the 
distribution of variables was determined by 
the Kolmogorov-Smirnov test. Anthropo-
metric measurements, dietary intakes and 
biochemical parameters of subjects in two 
groups at baseline were compared using in-
dependent sample t-test. 
Analysis of covariance was used to 
identify any differences in biochemical pa-
rameters between two groups after inter-
vention, adjusting for baseline measure-
ments and covariates. The changes in anth-
ropometric measurements, dietary intakes 
and biochemical parameters between the 
beginning and end of the study were com-
pared by paired sample t-test. The percen-
tage of changes in variables after interven-
tion was determined by formula: [(after val-
ues – before values) / before values] × 100. 
P value of < 0.05 was considered statistically 
significant. 
 
Results 
 
Anthropometric characteristics and 
dietary intakes of participants at the begin-
ning and end of the study are shown in Ta-
ble 1. There were no significant differences 
between and within groups in weight and 
BMI at the beginning of the study and after 
8 weeks of intervention. Cholesterol intake 
was significantly different between placebo 
and omega-3 fatty acids group at the begin-
ning of the study (P = 0.04). No significant 
differences in energy and other dietary in-
takes were observed between two groups at 
baseline. Total energy and nutrient intakes 
also did not change significantly in any of 
the groups during the study. Mohammadi & Rafraf.: Benefits of Omega-3 Fatty Acids Supplementation … 
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Metabolic parameters of subjects at 
baseline and after 8 weeks intervention are 
shown in Table 2.  
 
Table1: Characteristics and dietary intakes of women with PCOS at baseline and after 8 weeks 
intervention 
 
 
Variable 
Measurement   Placebo  Omega-3 fatty acids 
period  (n=31)   (n=30) 
Age (yr)  Baseline  27.73 ± 4.53  27.33 ± 4.27 
Weight (kg)  Baseline 
After intervention 
74.93 ± 9.95 
75.08 ± 9.88 
73.65 ± 8.87 
73.41 ± 8.88 
BMI (kg/m2)  Baseline 
After intervention 
28.77 ± 2.92 
28.83 ± 2.94 
28.67 ± 3.21 
28.58 ± 3.30 
Energy (kcal/day)  Baseline 
After intervention 
1734.50 ± 408.08 
1680.13 ± 367.75 
1741.80 ± 419.13 
1668.14 ± 415.30 
Carbohydrate (g/day)  Baseline 
After intervention 
214.63 ± 63.49 
216.10 ± 52.83 
223.67 ± 65.90 
209.36 ± 51.50 
Protein (g/day)  Baseline 
After intervention 
62.81 ± 19.47 
62.10 ± 18.70 
63.58 ± 19.19 
61.71 ± 21.93 
Total Fat (g/day)  Baseline 
After intervention 
66.97 ± 21.95 
65.75 ± 19.84 
64.98 ± 21.18 
64.56 ± 20.06 
SFA (g/day)  Baseline 
After intervention 
17.74 ± 6.59 
17.27 ± 6.30 
16.79 ± 6.20 
18.05 ± 6.82 
MUFA (g/day)  Baseline 
After intervention 
20.33 ± 6.20 
21.06 ± 7.11 
18.25 ± 6.72 
19.73 ± 6.87 
PUFA† (g/day)  Baseline 
After intervention 
20.89 ± 8.65 
19.07 ± 7.62 
19.97 ± 9.55 
17.76 ± 6.81 
Cholesterol (mg/day)  Baseline 
After intervention 
203.10 ± 39.36 
187.61 ± 45.78 
183.36 ± 34.52٭ 
191.42 ± 38.06 
BMI: body mass index, SFA: Saturated fatty acid, MUFA: Monounsaturated fatty acid, PUFA: Polyunsatu-
rated fatty acid 
Data are presented as mean ± SD 
† Excluding the PUFA from the supplement 
٭Significant difference between two groups at baseline (P < 0.05, independent sample t-test) 
 
Table 2: Metabolic parameters of women with PCOS at baseline and after 8 weeks intervention 
 
variable 
          Placebo (n=31) 
Baseline             after intervention 
Omega-3 fatty acids (n=30) 
       Baseline                  after intervention 
TC (mg/dl)  188.10 ± 29.21           186.63 ± 25.89 
 
125.73 ± 28.49           120.23 ± 28.52 
 
117.41± 31.53             117.25 ± 27.44 
 
44.86 ± 6.11              45.33 ± 4.49 
 
4.29 ± 1.04                  4.17 ± 0.84 
 
2.71 ± 0.99                2.64 ± 0.79 
 
2.84 ± 0.73                 2.67 ± 0.67 
 
146.58 ± 36.82            143.22 ± 37.07 
 
186.60 ± 32.45         170.33 ± 32.03 a,b 
 
TG (mg/dl)  126.97 ± 29.50          119.13 ± 26.04 a 
 
LDL-C (mg/dl)  118.06 ± 29.39       102.25 ± 29.59 a,b 
 
HDL-C (mg/dl)  43.13 ± 6.55             45.86 ± 6.53a 
 
TC/HDL-C  4.40 ± 0.93             3.75 ± 0.70 a,b 
 
LDL-C/HDL-C  2.80 ± 0.81           2.25 ± 0.64 a,b 
 
TG/HDL-C  3.04 ± 0.97               2.66 ± 0.78 
 
PON1(IU/ml)  138.66 ± 30.14          159.04 ± 34.17 a,b 
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TC: total cholesterol, TG: triglyceride, LDL-C: low density lipoprotein, HDL-C: high density lipoprotein, PON1: paraoxonase 1  
Data are presented as mean ± SD 
aSignificant difference within groups after intervention (P < 0.05, paired sample t-test) 
bSignificant difference between groups after intervention (P < 0.05, analysis of covariance) 
 
There was no significant difference 
between 2 groups in terms of serum lipids 
and PON1 activity at baseline. 
Results of analysis of covariance 
showed statistically significant differences 
between two studied groups in serum levels 
of TC, LDL-C, PON1 activity (P = 0.002, P 
= 0.003 and P  = 0.048, respectively), 
TC/HDL-C and LDL-C/HDL-C ratio (P = 
0.009 for both) at the end of the study, ad-
justed for energy, PUFA and cholesterol in-
takes and baseline values. Changes in serum 
TG and HDL-C levels and TG/HDL-C ra-
tio were not significant.  Supplementation 
with omega-3 fatty acids resulted in 12.8% 
and 19.7% reduction in TC/HDL and 
LDL/HDL ratio and 16.3% increase in se-
rum PON1 activity, in comparison to pla-
cebo group. 
As shown in Table 2, significant de-
crease in serum levels of TC, LDL-C (P < 
0.001 for both), TG (P = 0.024), TC/HDL-
C and LDL-C/HDL-C ratio (P < 0.001 for 
both) and TG/HDL-C ratio (P = 0.004) was 
obtained in omega-fatty acids group at the 
end of the study compared with baseline 
values. Serum HDL-C levels and PON1 ac-
tivity also increased significantly in omega-3 
fatty acids group at the end of the interven-
tion in comparison to the beginning of the 
study (P  = 0.018 and P  = 0.001, respec-
tively). 
 
Discussion 
 
Based on results (Table 1) we did not 
find any significant changes in weight, BMI, 
energy and macronutrient intakes within 
omega-3 fatty acids and placebo groups 
during the study. Our results were in accor-
dance with a previous study which reported 
that omega-3 supplementation by dose of 4 
g/day for 8 weeks, had no significant effects 
on BMI of PCOS patients with nonalcoholic 
fatty liver disease [13]. Six week supplemen-
tation with 3.5 g/day fish oil in women with 
PCOS did not change weight and BMI sig-
nificantly [18]. No other published data ex-
ists about the effects of omega-3 fatty acids 
in PCOS patients. Woodman et al. and Tsi-
touras et al. reported similar findings in stu-
dies on type 2 diabetes and healthy older 
subjects, respectively [19, 20].  
According to Table 1, overall energy 
intakes of subjects in both groups was not 
significantly different at the end of the study 
compared with baseline values, so no signifi-
cant changes in weight and BMI of all sub-
jects would be partially expected. 
We observed that supplementation 
with omega-3 fatty acids lead to improve-
ment in lipid profiles (Table 2). Cussons et 
al. and Vargas et al. reported significant re-
duction in serum TG levels in PCOS pa-
tients after supplementation with EPA and 
DHA, but serum TC, LDL-C and HDL-C 
concentrations remained unchanged [13, 18]. 
The beneficial effects of omega-3 fatty acids 
in reducing serum TG levels were demon-
strated in other studies in obese subjects [21] 
and diabetic patients [19]. Supplementation 
with omega-3 fatty acids resulted in signifi-
cant reduction in serum TG and increase in 
HDL-C levels in individuals with visceral 
obesity [22]. Fish oil supplementation re-
duced serum LDL-C levels in healthy sub-
jects and diabetic patients, respectively [23, 
24]. Our trial confirmed the results of men-
tioned studies.  
Several mechanisms are suggested to 
explain the effects of omega-3 fatty acids on 
serum lipids.  The omega-3 fatty acids are 
natural ligands for some metabolic nuclear 
receptors including PPARs (peroxisome 
proliferator- activated receptors). Activation 
of these receptors by EPA and DHA re-
sulted in suppression of lipid synthesis and 
stimulation of  fatty acid oxidation in liver 
and muscle [25]. Fish oil feeding reduces 
cholesterol absorption and LDL-C synthesis, 
improves LDL receptor activity in liver, and 
increases fractional rate of catabolism of 
LDL-C [20, 23, 26]. Mohammadi & Rafraf.: Benefits of Omega-3 Fatty Acids Supplementation … 
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Increased incidence of atherosclerosis 
in patients with PCOS was reported in pre-
vious studies [8]. TC/HDL-C and LDL-
C/HDL-C ratio have been considered as 
atherogenic indices and recently, the TG/ 
HDL-C ratio has been proven to be a strong 
predictor of cardiovascular disease [27]. 
Based on results (Table 2) TC/HDL-C and 
LDL-C/HDL-C ratio were reduced in our 
patients after omega-3 fatty acids interven-
tion. These findings indicate that omega-3 
fatty acids might have protective role against 
atherosclerosis. The effects of omega- fatty 
acids on lipid profile are dose dependent 
[11]. So it seems that if dose or duration of 
supplementation in our study were more, 
significant differences in TG/HDL-C ratio 
also might be determined between 2 groups, 
at the end of the intervention. 
PON1 has antioxidant properties and 
accounts as a new marker of lipid peroxida-
tion [7]. PON1 prevents the generation of 
oxidized LDL and inactivates LDL-derived 
oxidized products when they are formed. 
PON1 is responsible for anti-atherosclerotic 
actions of HDL-C [28]. Serum PON1 levels 
were inversely associated to the risk of co-
ronary heart disease [29]. Some human and 
animal investigations have shown that intake 
of omega-3 fatty acids could improve anti-
oxidant status [14, 30, 31 ]. In our study, 
supplementation with omega-3 fatty acids 
increased PON1 activity (Table 2). There are 
limited studies on the effects of omega-3 
fatty acids on serum levels or activity of 
PON1. Intake of 1.88 g EPA and 1.48 g 
DHA per day for 8 weeks in patients with 
familial combined hyperlipidemia increased 
serum PON1 levels by 10% compared with 
baseline values [16]. Fish oil intervention for 
6 weeks in male Wistar rats elevated PON1 
activity [32]. Long chain omega-3 PUFAs 
affect PON1 gene expression and synthesis 
of this enzyme in liver via activation of 
PPAR-γ.  In  addition  changes  in fatty acid 
composition of HDL-C by dietary omega-3 
fatty acids may modulate fluidity of HDL-C 
and PON1 activity [33]. Our findings con-
firm the positive effects of omega-3 fatty 
acids on elevating PON1 activity as an im-
portant part of antioxidant system in PCOS 
patients.  
This study had some limitation. We 
did not measure other antioxidant enzymes 
in our subjects, which could help us for 
more precise evaluation. In addition, we stu-
died only overweight and obese PCOS pa-
tients so present results are not applicable to 
other PCOS women with different BMI 
range. 
 
Conclusion 
 
Oxidative stress and impaired serum 
lipids are contributed in early onset of cardi-
ovascular disease and other long-term com-
plications in PCOS patients. Our results 
suggest that omega-3 fatty acids could con-
stitute a helpful approach to decrease cardi-
ometabolic risks via both improvements in 
PON-1 activity as an antioxidant marker and 
reduction in some serum lipids ratios in 
these women. 
 
Acknowledgments 
 
We thank The Research Vice-Chan-
cellor and Nutritional Research Center of 
Tabriz University of Medical Sciences, Ta-
briz, Islamic Republic of Iran for the finan-
cial support; and the  women who 
participated in the study. The authors 
declare that there is no conflict of interest. 
 
 References 
 
[1]  Wu Y, Zhang J, Wen Y, Wang H, 
Zhang M, Cianflone K. Increased acyla-
tion-stimulating protein, C-reactive 
protein, and lipid levels in young 
women with polycystic ovary syndrome. 
Fertil Steril 2009; 91(1): 213-9. 
[2]  Baptiste CG, Battista MC, Trottier A, 
Baillargeon JP. Insulin and 
hyperandrogenism in women with 
polycystic ovary syndrome. J Steroid 
Biochem Mol Biol 2010; 122(1-3): 42-52. 
[3]  Gambinineri A, Pelusi C, Vicennati V, 
Pagotto U, Pasquali R. Obesity and the 
polycystic ovary syndrome. Int J Obes 
Relat Metab Disord 2002; 26(7): 883-96. Health Promotion Perspectives, Vol. 2, No. 2, 2012; P: 197-204  
 
203 
 
[4]  Fenkci V, Fenkci S, Yilmazer M, 
Serteser M. Decreased total antioxidant 
status and increased oxidative stress in 
women with polycystic ovary syndrome 
may contribute to the risk of 
cardiovascular disease. Fertil Steril 2008; 
8(1): 123-127. 
[5]  Sekhon LH, Gupta S, Kim Y, Agarwal 
A. Female infertility and antioxidants. 
Curr Womens Health Rev 2010; 6: 84-95. 
[6]  Ruder EH, Hartman TJ, Blumberg J, 
Goldman M. Oxidative stress and 
antioxidants: exposure and impact on 
female fertility. Hum Reprod Update 2008; 
14(4): 345-357. 
[7]  Goswami B, Tayal D, Gupta N, Mallika 
V. Paraoxonase: a multifaceted bio-
molecule. Clin Chim Acta 2009; 410(1-2): 
1-12. 
[8]  Dursun P, Demirtas E, Bayrak A, Yarali 
H. Decreased serum paraoxonase 
1(PON1) activity: an additional risk 
factor for atherosclerotic heart disease 
in patient with PCOS? Hum Reprod 
2005; 21(1): 104-108. 
[9]  Mohamadin AM, Habib FA, Elahi TF. 
Serum paraoxonase 1 activity and 
oxidant/antioxidant status in Saudi 
women with polycystic ovary syndrome. 
Pathophysiology 2010; 17(3): 189–196. 
[10]  Kasim-Karakas SE, Almario RU, 
Gregory L, Wong R, Todd H, Lasley 
BL. Metabolic and endocrine effects of 
a polyunsaturated fatty acid-rich diet in 
polycystic ovary syndrome. J Clin 
Endocrinol Metab 2004; 89(2): 615–620. 
[11]  Oh R. Practical applications of fish oil 
(Omega-3 fatty acids) in primary care. J 
Am Board Fam Pract 2005; 18(1): 28-36. 
[12]  Ruxton CH, Reed SC, Simpson MJA, 
Millington KJ. The health benefits of 
omega-3 polyunsaturated fatty acids: a 
review of the evidence. J Hum Nutr Diet 
2004; 17(5): 249-259. 
[13]  Cussons AJ, Watts GF, Mori TA, 
Stuckey BGA. Omega-3 fatty acid 
supplementation decreases liver fat 
content in polycystic ovary syndrome: A 
randomized controlled trial employing 
proton magnetic resonance spectrosc-
opy. J Clin Endocrinol Metab 2009; 94(10); 
3842-3848. 
[14]  [14] Sarbolouki SH, jalali M, Dorosty 
AR, jazayery SA, Eshraghian MR, Ebadi 
SAR ,et al. Effects of EPA and vitamin 
E on serum enzymatic antioxidants and 
peroxidation indices in patients with 
type II diabetes mellitus. Iranian J Publ 
Health 2010; 39(3): 82-91. 
[15]  Tayyebi-Khosroshahi H, Houshyar J, 
Tabrizi A, Vatankhah AM, Razzaghi 
Zonouz N, Dehghan-Hesari R. Effect 
of omega-3 fatty acid on oxidative stress 
in patients on hemodialysis. Iran J Kidney 
Dis 2010;4(4):322-6. 
[16]  Calabresi L, Villa B, Canavesi M, Sirtori 
CR, James RW, Bernini F, et al. An ω-3 
polyunsaturated fatty acid concentrate 
increases plasma high-density lipoprot-
ein 2 cholesterol and paraoxo-nase 
levels in patients with familial combined 
hyperlipidemia.  Metabolism  2004; 53(2): 
153-158. 
[17]  Ozkaya M, Cakal E, Ustun Y, Engin-
Ustan Y. Effect of metformin on serum 
visfatin levels in patients with polycystic 
ovary syndrome. Fertil Steril 2010; 93(3): 
880-884. 
[18]  Vargas ML, Almario RU, Buchan W, 
Kim K, Karakas SE. Metabolic and 
endocrine effects of long-chain versus 
essential omega-3 polyunsaturated fatty 
acids in polycystic ovary syndrome. 
Metabolism 2011; 60(12): 1711-1718. 
[19]  Woodman RJ, Mori TA, Burke V, 
Puddey IB, Watts GF, Beilin LJ. Effects 
of purified eicosapentaenoic and 
docosahexaenoic acids on glycemic 
control, blood pressure, and serum 
lipids in type 2 diabetic patients with 
treated hypertension. Am J Clin Nutr 
2002; 76(5): 1007-1015. 
[20]  Tsitouras PD, Gucciardo F, Salbe AD, 
Heward C, Harman SM. High omega-3 
fat intake improves insulin sensitivity 
and reduces CRP and IL6, but does not 
affect other endocrine axes in healthy 
older adults. Horm Metab Res  2008; 
40(3): 199-205. 
[21]  Itoh M, Suqanami T, Satoh N, 
Tanimoto-Koyama K, Yuan X, Tanaka 
M, et al. Increased adiponectin secretion 
by highly purified eicosapentaenoic acid 
in rodent models of obesity and human 
obese subjects. Atheroscler Thromb Vasc 
Biol 2007; 27(9): 1918-25. 
[22]  Chan DC, Watts GF, Barrett PH, Beilin 
LJ, Mori TA. Effect of atorvastatin and 
fish oil on plasma high sensitive C-
reactive protein concentrations in Mohammadi & Rafraf.: Benefits of Omega-3 Fatty Acids Supplementation … 
  
204 
 
individuals with visceral obesity. Clin 
Chem 2002; 48(6 Pt 1): 877-83. 
[23]  Illingworth DR, Harris WS, Connor 
WE. Inhibition of low density 
lipoprotein synthesis by dietary omega-3 
fatty acids in humans. Arterioscler Thromb 
Vasc Biol 1984; 4(3): 270-5. 
[24]  Rashidi H, Aryanpoor H. Comparison 
between effects of fish oil and corn oil 
supplementation on serum lipids among 
type 2 diabetic patients in Zahedan, 
2004-2005. Iranian Journal of Diabetes and 
Lipid Disorders  2007; 6(4): 359-366. (In 
Persain) 
[25]  Davidson MH. Mechanisms for the 
hypotriglyceridemic effect of marine 
Omega-3 Fatty Acids. Am J Cardiol 
2006; 98(4A): 27i-33i. 
[26]  Nestel PJ. Fish oil and cardiovascular 
disease: lipids and arterial function. Am 
J Clin Nutr 2000; 71(1 suppl): 228S-31S. 
[27]  Alkhouri N, Tamimi TA, Yerian L, 
Lopez R, Zein NN, Feldstein AE. The 
inflamed liver and atherosclerosis: a link 
between histologic severity of 
nonalcoholic fatty liver disease and 
increased cardiovascular risk. Dig Dis Sci 
2010; 55(9): 2644-2650. 
[28]  Costa LG, Vitalone A, Cole TB, 
Furlong CE. Modulation of 
paraoxonase (PON1) activity. Biochem 
Pharmacol 2005; 64(9); 541-550. 
[29]  Draganov DI, Teiber JF, Speelman A, 
Osawa Y, Sunahara R, La Du BN. 
Human paraoxonases (PON1, PON2, 
and PON3) are lactonases with 
overlapping and distinct substrate 
specificities.  J Lipid Res  2005; 46(6): 
1239-1247. 
[30]  Barbosa DS, Cecchini R, EI Kadri MZ, 
Rodriguez MA, Burini RC, Dichi I. 
Decreased oxidative stress in patients 
with ulcerative colitis supplemented 
with fish oil omega-3 fatty acids. 
Nutrition 2003; 19(10): 837-842. 
[31]  Erdogan H, Fadillioglu E, Ozgocmen S, 
Sogut S, Ozyurt B, Akyol O, Ardicoglu 
O. Effect of fish oil supplementation on 
plasma oxidant/antioxidant status in 
rats.  Prostaglandins Leukot Essent Fatty 
Acids 2004; 71(3): 149–152. 
[32]  Popovic T, Borozan S, Arsic A, 
Martacic JD, Vucic V, Trbovic A, et al. 
Fish oil supplementation improved liver 
phospholipids fatty acid composition 
and parameters of oxidative stress in 
male wistar rats. J Anim Physiol Anim 
Nutr  2011; doi: 10.1111/j.1439-
0396.2011.01216.x. 
[33]  Ferretti G, Bacchetti T. Effect of dietary 
lipids on paraoxonase-1 activity and 
gene expression. Nutr Metab Cardiovasc 
Dis 2010; 22(2): 88-94. 
 
 
 
 
 
 
 
  
 
 